COLTENE's Q2 Slump Is a Setup-If Dental Demand Stands Up in H2

COLTENE's first half shows stable demand but weaker profitability

The clean read of COLTENE's half-year is this: 0.8% local-currency sales growth is modest, but plausible for a consumable dental supplier, while a 5.1% EBIT margin against 8.8% in 2025 is the bigger issue. In other words, demand does not look dead. Profitability, however, has clearly weakened.

Why the half-year matters

COLTENE sells dental consumables and small equipment, so the business should benefit from repeat demand as long as dental practices keep treating patients. On that front, the signal is mixed but not obviously broken: management said demand remained fundamentally intact, and first-half sales were still up 0.8% in local currencies. The key question now is whether H2 delivers the expected recovery in orders and margins.

The debate: weak quarter or weak engine?

Bulls can point to improved order momentum already visible in June and to product launches that management said were well received. Bears will note that profitability is still far below 2025 levels, which makes this a "show me" stage rather than a finished turnaround. For now, the steadier signal is demand stability, while margin repair still needs confirmation.

Margin pressure is the main watchpoint

The quarter looks ugly, but the more important distinction is between a low-profit period and a weakening customer base. Reported sales still fell in the reporting currency, yet local-currency sales were up 0.8% in local currencies, and management said demand remained fundamentally intact. That keeps this as a test of whether H2 improves, not a final verdict on the business.

Product demand shows some strength

Not every region or category was strong, but there were meaningful bright spots. The EMEA region and the Infection Control business unit in particular recorded strong growth, and product launches in the Infection Control business unit were very well received by the market. That suggests at least parts of the portfolio still have traction with customers.

This does not mean the quarter was healthy across the board. Geopolitical pressure, temporary destocking in the US, and softer demand in some other regions still weighed on results. But for a consumable dental business, signs that some practices are still buying the products matter.

Lower gross margin keeps the bear case alive

The profit problem is clearer than the demand problem. EBIT dropped 23.6% to CHF 5.1m; EBIT margin at 5.1%, and management said the lower EBIT margin mainly reflected the lower gross margin, even as cost reductions helped offset part of the hit.

That is the harder issue to dismiss. Temporary noise can hit one quarter, but if gross margin remains weak, investors will have to ask whether pricing power has also weakened. Last year's first half showed a similar warning, with rising market uncertainty and temporary factors hurting volume and pricing at the same time. Until gross margin recovers, this still looks like a "show me" story.

Cash flow improved, but it is not full proof

Free cash flow improved to CHF 4.8m from CHF -0.3m, which is positive. But the release said that improvement was driven by optimized inventories and working capital. That is better operating discipline, not definitive proof that end demand or brand resilience has fully recovered.

Management is still targeting 9–10% EBIT margin for FY2026. Coming from a 5.1% H1 margin, that target will require real margin recovery, not just tighter spending.

What would settle the debate in the next two quarters?

• Improved order momentum, including confirmation that June's improvement was not a one-off
• Evidence that gross margin is recovering as management expects
• Broader stabilization beyond the strongest regions and product lines